Controversial Treatment Strategies in COPD: Pro/Con

Controversial Treatment Strategies in COPD: Pro/Con

Regular price
$29.99
Sale price
$29.99
Regular price
Sold out
Unit price
per 

Quantity

-

+

Available guideline based therapy for COPD is limited in ability to restore quality of life, prevent exacerbations, slow decline in lung function or prolong life. Given these limitations, Physicians are attempting new approaches to treatment and patients are willing to attempt therapies with limited evidence base. Further, recent cohort studies have exposed limitations in our current classification scheme for COPD, and there is speculation that reclassification of the disease will fuel the field to move forward. The session will have experts involved with development of several emerging and controversial therapies in COPD to assess the evidence base for existing and future use to treat our patients with COPD.

1- Improve understanding of the benefits and potential limitations of new evidence based treatments for patients with COPD including endobronchial valves and home based pulmonary rehabilitation and more appropriately incorporate them into practice

2- Improve understanding of the limitations in evidence base and the future potential of available but controversial treatments for COPD including stem cell therapy and medical marijuana

3- Learn new concepts from large cohort studies that could be applied to the re-classification of COPD and understand the potential benefits and limitations of proceeding with disease reclassification

Carolyn L. Rochester, MD: Home Based Pulmonary Rehab Is Safe and Effective: PRO

Dirk-Jan Slebos, MD, PhD: Endobronchial Valves Are Effective and Should Be Broadly Accessible: PRO

Frank C. Sciurba, MD: Endobronchial Valves Are Effective and Should Be Broadly Accessible: CON

Daniel J. Weiss, MD, PhD, ATSF: Stem Cell Therapy Is a Real Hope for COPD Patients: PRO

Marilyn K. Glassberg, MD: Stem Cell Therapy Is a Real Hope for COPD Patients: CON

James D. Crapo, MD: Reclassification of COPD Is Achievable and Will Improve Treatment: PRO

Ruth Tal-Singer, PhD: Reclassification of COPD Is Achievable and Will Improve Treatment: CON

You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!